Supplementation With Amino Acid Rehabilitative Therapy in TBI (SmART-TBI): A Randomized Placebo-Controlled Trial to Improve Sleep

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The most persistent and disabling postconcussive symptoms following mild traumatic brain injury (mTBI) are sleep disturbances and cognitive dysfunction, with few tractable interventions currently available. Here, a novel therapy will be tested consisting of dietary supplementation with branched chain amino acids (BCAA), based on the study team's previous preclinical work showing restoration of glutamate neurotransmitter balance in sleep and memory circuits. Supplementation with Amino acid Rehabilitative Therapy in TBI (SmART-TBI) is a randomized, placebo-controlled, double-blinded, exploratory clinical trial of BCAA intended to establish the feasibility, acceptability, and limited efficacy of long-term BCAA to improve sleep and cognition in Veterans with mTBI. These results will inform the optimal study design of a future, full-scale randomized controlled trial, including the identification of the proper dose and duration of BCAA to improve sleep and the potential subpopulations of Veterans with mTBI that may benefit the most.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Be Veterans (male and female; any race; 18-65 years of age)

• Be English speaking

• Be accessible via phone

• Be non-decisionally impaired

• Attest to there being no chance of being or becoming pregnant during the study (if female)

• Attest to no history of maple syrup urine disease or known family history of maple urine syrup disease

• Have either a history of self-reported sleep disturbances, either as determined via the Insomnia Severity Index, Functional Outcomes of Sleep Questionnaire or Epworth Sleepiness Scale, clinical assessment, and/or a history of self-reported cognitive disturbance (e.g., poor memory, concentration, attention)

• Not have an allergy to sucralose

• Not be a shift worker (e.g. have worked night or rotating shifts more than twice in the past month)

• Not have a diagnosis of amyotrophic lateral sclerosis

• Not be currently supplementing their diet with branched chain amino acids

• Not be starting another sleep intervention (e.g., positive airway pressure therapy for sleep apnea, sedative-hypnotic medication, or cognitive behavioral therapy for insomnia) during the study

⁃ if already engaged in another sleep intervention, this must be stable and not undergo further changes during the study

• Meet diagnostic criteria for TBI using a validated clinical interview

Locations
United States
Oregon
VA Portland Health Care System, Portland, OR
RECRUITING
Portland
Contact Information
Primary
Miranda M Lim, MD PhD
miranda.lim@va.gov
(503) 220-8262
Backup
Jonathan E Elliott, PhD
jonathan.elliott@va.gov
(503) 220-8262
Time Frame
Start Date: 2021-06-01
Estimated Completion Date: 2025-09-30
Participants
Target number of participants: 200
Treatments
Experimental: BCAA 20g/daily
Branched Chain Amino Acids, 10g BID x 12 weeks
Experimental: BCAA 40g/daily
Branched Chain Amino Acids, 20g BID x 12 weeks
Experimental: BCAA 60g/daily
Branched Chain Amino Acids, 30g BID x 12 weeks
Placebo_comparator: Placebo 20g/daily
Protein without BCAA, 10g BID x 12 weeks
Related Therapeutic Areas
Sponsors
Leads: VA Office of Research and Development
Collaborators: Oregon Health and Science University, Children's Hospital of Philadelphia

This content was sourced from clinicaltrials.gov